Josh Brown: Biotech growth stocks immune to disruption risk

Josh Brown, CEO of Ritholtz Wealth Management, made a pointed assertion connected CNBC's Halftime Report this week astir large-cap biotech: "These are maturation stocks wherever you don't person to interest astir disruption. They're breaking out." His reasoning is that companies dealing successful molecules, proteins, and objective trials inhabit a fundamentally antithetic hazard class than bundle oregon media. AI tin disrupt a level overnight; it cannot disrupt a decade-long cause support process.

Large-cap biotech does bask a structural insulation from the overnight level disruption that has hollowed retired tech companies. But the assemblage faces its ain slow-motion disruption forces — patent cliffs, biosimilar competition, and authorities cause pricing betterment — that are conscionable arsenic susceptible of destroying revenue. These are antithetic disruption mechanisms, and conflating them leads to unsighted positions.

Brown's halfway thesis holds up. The 5 names helium and his workfellow highlighted — Amgen, AbbVie, Gilead, Biogen, and Eli Lilly — run successful a domain wherever competitory moats are built successful laboratories implicit galore years, not successful information centers implicit months. A caller AI exemplary cannot render a biologic cause obsolete the mode it tin render a contented level oregon a hunt motor irrelevant. The FDA support process, which typically spans a decennary from find to market, creates a structural clip buffer that nary bundle institution enjoys.

The year-to-date terms show crossed these names reflects that comparative resilience. Amgen is up 16% year-to-date, and Gilead has gained 21% successful 2026 truthful far. Both are good up of the broader iShares Biotechnology ETF (IBB), which is up astir 3% year-to-date. These are not stocks riding a wide biotech wave; they are outperforming the assemblage itself.

READ: The expert who called NVIDIA successful 2010 just named his apical 10 AI stocks

Brown besides noted that AI volition apt help these companies alternatively than wounded them, accelerating cause find and objective proceedings analysis. That is simply a tenable anticipation and 1 that organization investors look to share. Gilead carries 93% organization ownership, and Amgen sits astatine 85%. Large wealth managers are not treating these arsenic fragile positions.